Reviva to Present Brilaroxazine Topline Data for Long-Term OLE Portion of RECOVER Study in Schizophrenia at 2025 SIRS Congress

Rhea-AI Summary

Reviva Pharmaceuticals (NASDAQ: RVPH) has announced it will present topline data from the long-term open label extension portion of its Phase 3 RECOVER study for brilaroxazine in schizophrenia treatment at the 2025 SIRS Congress in Chicago.

The presentation, titled 'Brilaroxazine Phase 3 Recover 52-Week Open-Label Evaluation of Efficacy and Safety over 12 Months in Stable Schizophrenia Participants,' will be delivered by Dr. Laxminarayan Bhat, Founder & CEO of Reviva Pharmaceuticals, on Sunday, March 30th from 10:30 AM to 12:00 PM CST.

The company, which focuses on developing therapies for central nervous system (CNS), inflammatory and cardiometabolic diseases, will showcase these results at the Schizophrenia International Research Society (SIRS) Congress, taking place March 29 to April 2, 2025.

CUPERTINO, Calif., March 30, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, announced today topline data from the long-term open label extension portion of the Phase 3 RECOVER study evaluating brilaroxazine in schizophrenia will be presented as part of an oral presentation at the 2025 Congress of the Schizophrenia International Research Society (SIRS) taking place March 29 to April 2, 2025 in Chicago, Illinois, U.S.

Details for the oral presentation can be found below:

Title: Brilaroxazine Phase 3 Recover 52-Week Open-Label Evaluation of Efficacy and Safety over 12 Months in Stable Schizophrenia Participants

Session: Pharmaceutical Pipeline

Date and Time: Sunday, March 30^th from 10:30 AM – 12:00 PM ET CST

Presenter: Dr. Laxminarayan Bhat, Founder & CEO, Reviva Pharmaceuticals

Abstracts and additional details can be found at the SIRS 2025 website.

About Reviva 
Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva's current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva's pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries.

Corporate Contact:
Reviva Pharmaceuticals Holdings, Inc.
Laxminarayan Bhat, PhD
www.revivapharma.com

Investor Relations Contact:
LifeSci Advisors, LLC
Bruce Mackle
bmackle@lifesciadvisors.com

FAQ

What are the key findings from RVPH's Phase 3 RECOVER study for brilaroxazine?

The topline data from the 52-week open-label extension study will be presented at the 2025 SIRS Congress on March 30th, 2025. Specific findings have not yet been disclosed.

When and where will Reviva Pharmaceuticals (RVPH) present its brilaroxazine study results?

RVPH will present at the 2025 SIRS Congress in Chicago on Sunday, March 30th, from 10:30 AM to 12:00 PM CST.

What is the duration of the RVPH RECOVER study for brilaroxazine in schizophrenia?

The RECOVER study includes a 52-week (12-month) open-label extension evaluation of brilaroxazine in stable schizophrenia participants.

Which therapeutic areas does RVPH focus on with brilaroxazine development?

RVPH develops therapies for central nervous system (CNS), inflammatory and cardiometabolic diseases, with brilaroxazine being evaluated for schizophrenia treatment.